FORMULATION, EVALUATION AND OPTIMIZATION OF SUSTAINED RELEASE MICROCAPSULES OF LORNOXICAM PREPARED WITH GUM DIKAMALI & PECTIN EXTRACTED FROM DILLENIA INDICA

SIVASANKAR MOHANTY*, G. KRISHNA MOHAN and M. SUNITHA REDDY

Centre for Pharmaceutical Sciences, Institute of Science & Technology, Jawaharlal Nehru Technological University, HYDERABAD (A.P.) INDIA

ABSTRACT

The present research work was focused on the development of microcapsules using natural polymers like gum dikamali and pectin extracted from Dillenia indica by employing ionotropic gelation method with Lornoxicam as a model drug. The microcapsules were prepared with combination of different concentration of gum and pectin and the formulations were optimized on the basis of drug release up to 24 hrs. The drug and polymers were subjected for compatibility studies using FTIR & DSC. The formulated microcapsules were characterized for particle size, percentage drug entrapment efficiency, surface morphology, mucoadhesivity and in vitro drug release study. The microcapsules exhibited good mucoadhesive property in the in vitro wash-off test and also showed high percentage drug entrapment efficiency. The optical microscopic studies revealed that mean particle size of all the formulations was found in the range of 912.16 ± 16.33 to 998.14.12 μm and percentage of drug entrapment was between 39.28% - 88.92%. The study has revealed that natural materials can be used for formulation of controlled release microcapsules and will provide ample opportunities for further study.

Key words: Lornoxicam, Gum dikamali, Dillenia indica, Pectin, Ionotropic gelation method, Microcapsules.

INTRODUCTION

Lornoxicam, a congener of tenoxicam, is a new NSAID belonging to the oxicam class. It is a strong analgesic and antiinflammatory properties, which belongs to biopharmaceutical class II (Low solubility and high permeability). The bioavailability of
Lornoxicam is 90% – 100%. Because of its relatively short plasma half-life (3-5 hr), it is prescribed to take lornoxicam in divided daily doses either twice or thrice daily in order to maintain the therapeutic plasma concentration. These characteristics make lornoxicam a suitable candidate for developing into sustained release microcapsules\(^1\). In the present study, it is aimed to formulate, evaluate & optimize the sustained release microcapsules prepared with hydrophilic polymers like gum dikamali & pectin extracted from *Dillenia indica*. Gum dikamali is *Gardenia gummifera* belonging to the family Rubiaceae, are medium sized trees growing all over India. The gum-resin oozing out from the leaf buds of these trees is called Dikamali. *D. indica* is commonly known as Elephant-apple, Indian catmon in English, *Ou tenga* in Assamese, *Lisora* in Hindi and *Bahubar* in Sanskrit\(^2\). Extracts of *D. indica* contain mainly pectous polysaccharides, which can be extracted by precipitation with acetone. Pectin is a very promising biopolymer to construct drug carriers for controlled drug delivery because of its gelling, film forming, binding properties, biocompatibility and stability towards acidic media, and non-toxicity. The natural polymer selected for the present study was *Dikamali*. Dikamali is a hydrophilic matrix forming agent\(^3\). Natural polysaccharides extracted from *D. indica* and gum dikamali were used to formulate microcapsules.

**EXPERIMENTAL**

**Materials used**

Lornoxicam was obtained from Inventia Health Care Pvt. Ltd. The Girijan Co-operative Corporation Ltd. (Visakhapatnam, India) has supplied Gum Dikamali. Sodium alginate (having a viscosity of 5.5 cps in a 1% w/v aqueous solution at 25 OC), calcium chloride and heavy liquid paraffin were procured from SD Fine Chemicals Pvt. Ltd., Mumbai, India. The fruit of *Dillenia indica* was procured from local market of Balasore (Odisha) and was confirmed by local people. All other chemicals were of analytic grade.

**Methods**

**Extraction of pectin**

At first the fruits were collected and were cut into small pieces with knife. The chopped pieces of the fruits were kept in a beaker containing distilled water with ratio 1:1.5. The beaker was then placed on the heating mantle with temp. 60\(^\circ\)C for 5-6 hrs. After about 6 hours the slurries were strained through a Buchner funnel and the filtrate was kept in refrigerator in a beaker for overnight for sedimentation. The decanted filtrate was taken out of refrigerator and the supernatant was poured into a clean and dry beaker of 1 L size. The
supernatant was evaporated to 1/5th of its volume by heating mantle at 60°C. The concentrated samples were washed with acetone and dried at 50 to 60°C in a hot air oven for 4 hrs. On drying, the sample became hard and brownish in colour. The powdered samples were passed through sieve No. 120 & were stored in desiccators under sealed conditions for further study.

Preformulation studies

Drug excipient compatibility studies

FTIR Studies

The FTIR-8400S spectrophotometer (Shimadzu, Japan) was used to obtain the infrared spectra of pure drug (Lornoxicam) and physical mixture containing drug and natural polymers. Samples were prepared in KBr (Potassium bromide) disks of 2 mg sample in 200 mg of KBr with the Scanning range was 400-4000 cm⁻¹.

DSC Studies

The DSC thermograms of the pure drug and optimized formulation were obtained using the Perkin Elmer JADE DSC system, to identify any interaction between the components of drug and natural polymers.

Preparation of Lornoxicam microcapsules

Aqueous dispersion of Pectin, Dikamali & Sodium alginate was prepared and was kept for overnight. Appropriate amount of Lornoxicam (2:1 polymer: drug) was dispersed in the above dispersion until a uniform dispersion was obtained. The bubble free dispersion was added drop wise, through a disposable syringe (nozzle of 1.0 mm inner diameter) to a 200 mL of a gently agitated solution of the cross linking agent (CaCl₂) with different concentration i.e. 2%, 4% & 6% at room temperature separately as shown in Table 1. The distance of falling of the drops was 5 cm. The gelled particles thus formed were allowed to remain in the cross linking solution up to time period of 15 mins. The particles were subsequently washed with purified water, in order to remove Cl⁻ ions and separated by filtration. The particles were air dried for 24 hrs and stored in a desiccator at room temperature. Similarly Dikamali-pectin microcapsules were prepared without using sodium alginate by the above gelation technique.

UV Spectrum analysis of Lornoxicam

The solution (pH 1.2 & pH 6.8) was scanned in the range of 200 to 400 nm to fix the maximum wavelength and UV spectrum was obtained by using UV Spectrophotometer.
Characterization of microcapsules

**Percentage yield**

Percent yield of microspheres was determined by the amount of material recovered in the form of microspheres in relation to total amount of particulate matter taken in the form of drug and polymers by using following Eq. –

\[
\text{Percent yield} = \frac{\text{Microspheres recovered (mg)}}{\text{Initial amount of drug & polymers (mg)}} \times 100
\]

**Entrapment efficiency**

The drug entrapment efficiency of microcapsules was estimated by dispersing the microspheres in 100 mL of phosphate buffer at 6.8 by vigorous shaking on mechanical shaker (Remi Motors, Mumbai) for 12 hr. Then, the solution was filtered, and the Lornoxicam content was assayed by an UV spectrophotometer. The entrapment efficiency of microcapsules was calculated using the following formula.

\[
\text{Entrapment efficiency} = \frac{\text{Estimated percentage drug loading}}{\text{Theoretical percentage drug loading}} \times 100
\]

**Particle size**

The particle size of the microspheres was determined by using optical microscopy method. Approximately 50 microspheres were counted for particle size using a calibrated optical microscope.

**Swelling studies**

The swelling studies of uncoated beads were performed in aqueous swelling media with pH 6.8 buffer at 37.5 ± 0.5°C. The swelling ratio, \( S_{wt} \), was calculated from the following expression.

\[
S_{wt} = \left[ \frac{(W_t - W_0)}{W_0} \right] 100
\]

Where \( W_t \) and \( W_0 \) are weight of sample swollen at time \( t \) (10 hrs) and weight of the original sample, respectively.

**Wash-off test for microcapsules**

The mucoadhesive properties of the microspheres were evaluated by *in vitro* wash-off test. A 1 cm by 1 cm piece of rat stomach mucosa was tied onto a glass slide (3 inch by
1 inch) using thread. Microcapsules (50) were spread onto the wet rinsed tissue specimen, and the prepared slide was hung onto one of the groves of a USP tablet disintegrating test apparatus. The disintegrating test apparatus is operated such that the tissue specimen was given regular up and down movements in beaker containing the phosphate buffer (pH 6.8). At the end 10\textsuperscript{th} hrs, the number of microspheres still adhering onto the tissue was counted\textsuperscript{12}.

**In vitro release study**

In vitro dissolution of all the formulations was conducted by using USP Dissolution apparatus I. Microspheres equivalent to 16 mg of Lornoxicam were filled in the capsules of size 2. Filled capsules were placed in the baskets of dissolution apparatus. The dissolution media used were 0.1 N HCl for first 2 hr and phosphate buffer pH 6.8 for remaining time. The temperature was maintained at 37 ± 0.5°C and rotation was set at 50 rpm. 10.0 mL of sample was taken, filtered, and analyzed at 373.6 nm using double beam spectrophotometer to get percentage drug release versus time profile. Fresh medium was replaced for each sample taken out of the apparatus.

**RESULTS AND DISCUSSION**

**Calibration curve of Lornoxicam**

The $\lambda_{\text{max}}$ of Lornoxicam at 10 μg/mL concentration was found to be 373.6 nm. The standard calibration curve was found to be linear in the range of 2-14 μg/mL.
The FT-IR spectra of optimized formulation was compared with the FT-IR spectrum of pure drug. The pure drug Lornoxicam exhibited its characteristic absorption bands at 3099.61 cm\(^{-1}\) due to aromatic NH stretching and at 2924.1 cm\(^{-1}\) due to C-H stretching of CH\(_3\) group. The other prominent absorption bands appeared at 1642.5 cm\(^{-1}\) due to stretching vibrations of C=O of CONH, 1546.4 due to aromatic C=C and C=N stretching. The peaks at 1425.8 cm\(^{-1}\) and 1331.7 cm\(^{-1}\) corresponds to O=S=O group, 769.3 cm\(^{-1}\) due to C-Cl stretching vibrations. The IR spectra of optimized formulation exhibited all the characteristic absorption bands as that of pure drug Lornoxicam without any significant variations. It is clear from the spectra that, the drug has not undergone any kind of interactions with the excipients used and retained its identity in its formulation.

![Fig. 2 (a): FT-IR spectrum of pure Lornoxicam](image1)

![Fig. 2 (b): FT-IR spectrum of optimized formulation](image2)
DSC Studies

Differential scanning calorimetric analysis was also performed in order to establish the identity and integrity of drug in its pure form and also in the optimized formulation. The thermogram of the pure drug Lornoxicam showed an exothermic peak exhibiting its sharp melting point at 234.81°C and thermogram of optimized formulation showed exothermic peak at 224.77°C, indicating the absence of interaction between the drug and the excipients.

![DSC of pure Lornoxicam](image1.png)

**Fig. 3(a) DSC of pure Lornoxicam**

![DSC of optimized formulation](image2.png)

**Fig. 3 (b): DSC of optimized formulation**

Particle size analysis

Optical microscopy

The mean particle size of all the formulations was found to be in the range of 998.10 ± 14.12 to 912.16 ± 16.33 μm showed in (Table 1), and it was observed that the size increased with the increase in the concentration of *gum dikamali* and pectin in different ratio.

Yield of Lornoxicam microcapsules

The percentage yields of all the formulations were calculated and the yield was found to be in the range of 68.1-82.42% showed in (Table 1).
Drug entrapment efficiency

The percentage drug entrapment efficiency of microcapsules in all the formulations was found to be in the range of 39.28 ± 1.58 - 88.92 ± 1.37%. The formulation LX-13, which showed maximum drug entrapment efficiency of 88.92 ± 1.37%.

Table 1: Particle size, yield, entrapment efficiency, swelling studies & % mucoadhesion of lornoxicam loaded microcapsules

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Particle size (µm)</th>
<th>Yield (%)</th>
<th>Drug entrapment efficiency (%)</th>
<th>Swelling studies</th>
<th>% Mucoadhesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXM 1</td>
<td>Irregular</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LXM 2</td>
<td>Irregular</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LXM 3</td>
<td>912.1 ± 16.33</td>
<td>68.2</td>
<td>55.2 ± 1.2</td>
<td>32.6</td>
<td>41.4 ± 0.5</td>
</tr>
<tr>
<td>LXM 4</td>
<td>902.7 ± 12.22</td>
<td>72.7</td>
<td>61.9 ± 0.89</td>
<td>32.91</td>
<td>41.6 ± 0.53</td>
</tr>
<tr>
<td>LXM 5</td>
<td>918.7 ± 14.1</td>
<td>72.1</td>
<td>61.4 ± 1.21</td>
<td>35.71</td>
<td>42.3 ± 0.44</td>
</tr>
<tr>
<td>LXM 6</td>
<td>922.6 ± 10.91</td>
<td>82.6</td>
<td>78.9 ± 2.10</td>
<td>79.7</td>
<td>55.2 ± 0.21</td>
</tr>
<tr>
<td>LXM 7</td>
<td>927.2 ± 11.2</td>
<td>91.2</td>
<td>90.1 ± 0.89</td>
<td>80.1</td>
<td>56.3 ± 0.5</td>
</tr>
<tr>
<td>LXM 8</td>
<td>920.4 ± 13.76</td>
<td>90.7</td>
<td>89.6 ± 0.54</td>
<td>79.9</td>
<td>55.9 ± 0.25</td>
</tr>
<tr>
<td>LXM 9</td>
<td>911.9 ± 12.8</td>
<td>89.7</td>
<td>85.7 ± 0.21</td>
<td>69.24</td>
<td>45.3 ± 0.5</td>
</tr>
<tr>
<td>LXM 10</td>
<td>926.9 ± 9.61</td>
<td>92.7</td>
<td>91.9 ± 0.54</td>
<td>86.31</td>
<td>54.7 ± 0.21</td>
</tr>
<tr>
<td>LXM 11</td>
<td>919.8 ± 11.23</td>
<td>90.1</td>
<td>87.3 ± 0.11</td>
<td>76.7</td>
<td>47.32 ± 0.15</td>
</tr>
<tr>
<td>LXM 12</td>
<td>929.7 ± 14.72</td>
<td>93.6</td>
<td>87.8 ± 1.01</td>
<td>88.72</td>
<td>58.82 ± 0.11</td>
</tr>
<tr>
<td>LXM 13</td>
<td>944.0 ± 8.21</td>
<td>96.9</td>
<td>97.3 ± 2.21</td>
<td>89.1</td>
<td>59.2 ± 0.48</td>
</tr>
<tr>
<td>LXM 14</td>
<td>949.6 ± 7.98</td>
<td>96.1</td>
<td>92.4 ± 0.53</td>
<td>88.9</td>
<td>58.9 ± 0.33</td>
</tr>
<tr>
<td>LXM 15</td>
<td>946.2 ± 10.61</td>
<td>95.9</td>
<td>90.7 ± 1.02</td>
<td>91.34</td>
<td>56.32 ± 0.18</td>
</tr>
</tbody>
</table>

In vitro drug release

The in vitro drug release studies revealed that the formulation LX 13 showed a slow and sustained drug release of 100.2% at the end of 24 hr. The results indicated that increasing the concentration of pectin & dikamali with respect to the drug resulted in decreasing the drug release. The optimized formulation (LX 13) was compared with marketed formulation Lofecam SR (16 mg) showed almost same drug release.
CONCLUSION

The formulation LXM 13 containing drug: polymer ratio 1:2 was found to be the best formulation prepared by orifice ionic gelation technique. Regarding all properties evaluated in order to achieve objective of this study the novel formulation design facilitated the optimization and successful development of Lornoxicam microcapsules. Lornoxicam release from the mucoadhesive microcapsules was slow and extended over longer periods depending on composition of the polymers. These mucoadhesive microcapsules are thus, suitable for oral controlled release of Lornoxicam.

ACKNOWLEDGEMENT

Authors wish to thank Inventia Health Care Pvt Ltd., for proving gift sample of Lornoxicam and thank to Girijan Co-operative Ltd. (Vishakhapatnam, India) for providing natural gums for this study and special thanks to Jawaharlal Nehru Technological University for providing all the facilities to carry out the experiments.

REFERENCES


